Bevan DR, Donati F, Kopman AF. Reversal of neuromuscular blockade. Anesthesiology. 1992;77:785–805.
• Todd MM, Hindman BJ, King BJ. The implementation of quantitative electromyographic neuromuscular monitoring in an academic anesthesia department. Anesth Analg. 2014;119:323–31. Implementation of quantitative neuromuscular blockade monitoring resulted in a significant reduction in the incidence of incompletely reversed patients in the PACU.
• McLean DJ, Diaz-Gil D, Farhan HN, Ladha KS, Kurth T, Eikermann M. Dose-dependent association between intermediate-acting neuromuscular-blocking agents and postoperative respiratory complications. Anesthesiology. 2015;122:1201–13. Study which shows a neuromuscular blocking agent dose dependent association with increased risk of respiratory complications in the postoperative period; and also suggesting that the proper use of neostigmine guided by neuromuscular transmission monitoring results can help eliminate postoperative respiratory complications associated with neuromuscular-blocking agents.
Madsen MV, Staehr-Rye AK, Gatke MR, Claudis C. Neuromuscular blockade for optimising surgical conditions during abdominal and gynaecological surgery: a systemic review. Acta Anaesthesiol Scand. 2015;59:1–16.
Fuchs-Buder T, Hofmockel R, Geldner G, Diefenbach C, Ulm K, Blobner M. The use of neuromuscular monitoring in Germany. Anaesthesist. 2003;52:522–6.
Thilen SR, Hansen BE, Ramaiah R, Kent CD, Treggiari MM, Bhananker SM. Intraoperative neuromuscular monitoring site and residual paralysis. Anesthesiology. 2012;117:964–72.
Grayling M, Sweeney BP. Recovery of neuromuscular blockade: a survey of practice. Anaesthesia. 2007;62:806–9.
•• Checketts MR, Alladi R, Ferguson K, et al. Recommendations for standards of monitoring during anaesthesia and recovery 2015: Association of Anaesthesists of Great Britain and Ireland. Anaesthesia 2015. Guidelines for UK and Irish anesthetists for physiological monitoring of patients undergoing both sedation and general anaesthesia. Minimum standards for monitoring patients during and in recovery, with new sections discussing the role of monitoring depth of anaesthesia, neuromuscular blockade, and cardiac output.
Sasaki N, Meyer MJ, Malviya SA, Stanislaus AB, MacDonald T, Doran ME, Igumenshcheva A, Hoang AH, Eikermann M. Effects of neostigmine reversal of nondepolarizing neuromuscular blocking agents on postoperative respiratory outcomes: a prospective study. Anesthesiology. 2014;121:959–68.
Fuchs-Buder T, Meitelman C, Alla F, Grandjean A, Wuthrich Y, Donati F. Antagonism of low degrees of atracurium-induced neuromuscular blockade. Dose-effect relationships for neostigmine. Anesthesiology. 2010;112:34–40.
Fuchs-Buder T, Baumann C, De Guis J, Guerci P, Meistelman C. Low-dose neostigmine to antagonize shallow atracurium neuromuscular block during inhalational anaesthesia: a randomized controlled trial. Eur J Anaesth. 2013;30:594–8.
Naguib M, Kopman AF, Lien CA, Hunter JM, Lopez A, Brull SJ. A survey of current management of neuromuscular block in the United States and Europe. Anesth Analg. 2010;111:110–9.
Kopman AF, Eikermann M. Antagonism of non-depolarising neuromuscular block: current practice. Anaesthesia. 2009;64(Suppl 1):22–30.
Murphy GS, Szokol JW, Marymont JH, et al. Intraoperative acceleromyographic monitoring reduces the risk of residual neuromuscular blockade and adverse respiratory events in the postanesthesia care unit. Anesthesiology. 2008;109:389–98.
Murphy GS, Szokol JW, Marymont JH, et al. Residual neuromuscular blockade and critical respiratory events in the postanesthesia care unit. Anesth Analg. 2008;107:130–7.
Debaene B, Plaud B, Dilly M-P, Donati F. Residual paralysis in the PACU after a single intubating dose of nondepolorazing muscle relaxant with an intermediate duration of action. Anesthesiology. 2003;98:1042–8.
Arbous MS, Meursing AE, van Kleef JW, de Lange JJ, Spoormans HH, Touw P, Werner FM, Grobbee DE. Impact of anesthesia management characteristics on severe morbidity and mortality. Anesthesiology. 2005;102:257–68.